|
|
| Line 45: |
Line 45: |
| | </div> | | </div> |
| | </div> | | </div> |
| − |
| |
| − |
| |
| − |
| |
| − | <div class="contentbox">
| |
| − | <div class="content">
| |
| − | <span class="anchor-jump" id="merck"></span>
| |
| − | <div class="section"></div>
| |
| − | <h3> Merck </h3>
| |
| − |
| |
| − | <!-- Normaler Text -->
| |
| − | <article>
| |
| − | Merck is a leading company for products in the pharmaceutical and chemical sectors. Their expertise consists of three mayor sectors: Healthcare, Life Science and Performance Materials. This wide variety of subject areas ensures Mercks status as a global player. Their close collaboration with scientists ensures the high-quality of their products and know-how. Merck has supported the iGEM Bielefed-CeBiTec teams for seven years. We are grateful for their continues scientific support and expertise.
| |
| − | Back in August, we visited Merck to present our final project idea and the first results. Our visit was organized by Prof. Dr. Herget, who has been a great supporter of the iGEM-Teams Bielefeld for several years.
| |
| − |
| |
| − | </article>
| |
| − |
| |
| − | <!-- Grosses zentriertes Bild -->
| |
| − | <div class="figure large">
| |
| − | <img class="figure image" src="https://static.igem.org/mediawiki/2017/0/06/T--Bielefeld-CeBiTec--Merck-Olga-Markus.jpg">
| |
| − | <p class="figure subtitle"><b>Figure 2: </b> iGEM Bielefeld-CeBiTec 2017 team members Olga Schmidt and Markus Haak presenting our project in front of the Merck scientists. </p>
| |
| − | </div>
| |
| − |
| |
| − |
| |
| − | <article>
| |
| − |
| |
| − | The following discussion dealt particularly with possible <i>in vitro</i> and <i>in vivo</i> approaches and the ethical concerns regarding our project. They confirmed our idea to add <i>in vitro</i> experiments as an additional control for our project.
| |
| − | The moral concers have also been addressed. Therefore we designed a survey and asked for second opinions in a variety of meetings with ethicists. This eventuated in our report “ChImp - Chances and Implication of an Expanded Genetic Code”, from which we derive guidelines and recommendations for work awareness in science.
| |
| − | Visiting Merck is valuable in more than just one way: we did not just gain experience in holding a presentation in front of experienced researchers, but also received great advice for the future development of our project.
| |
| − | We are excited to visit Merck again next year to present our final results and the progress we have made.
| |
| − |
| |
| − |
| |
| − |
| |
| − | </article>
| |
| − |
| |
| − | <!-- Grosses zentriertes Bild -->
| |
| − | <div class="figure large">
| |
| − | <img class="figure image" src="https://static.igem.org/mediawiki/2017/9/9f/T--Bielefeld-CeBiTec--Merck-Gruppenfoto.jpg">
| |
| − | <p class="figure subtitle"><b>Figure 3: </b> iGEM Bielefeld 2017 team members Olga Schmidt and Markus Haak with representatives from the iGEM Bielefeld 2016 team and Merck.</p>
| |
| − | </div>
| |
| − |
| |
| − | </div>
| |
| − | </div>
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| − |
| |
| | | | |
| | | | |
